Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Significance: Metabolic plasticity allows cancer cells to adjust their metabolic phenotypes to adapt in hostile environments. There is an urgent need to understand the cross-talk between gene regulation and metabolic pathways underlying cancer metabolic plasticity. We establish a theoretical framework to decode the coupling of gene regulation and metabolic pathways. Our work characterizes a hybrid metabolic state where cells can use both glycolysis and oxidative phosphorylation (OXPHOS) and a possible metabolically inactive state where cells have low activity of both glycolysis and OXPHOS. We show that targeting both OXPHOS and glycolysis may be necessary to eliminate cancer aggressiveness. Our work serves as a platform to target abnormal metabolism in cancer by modulating both genes and metabolic pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Unlike normal cells, cancer cells largely depend on glycolysis to produce energy even in the presence of oxygen, referred to as the Warburg effect (3) or aerobic glycolysis.”
BackgroundWhat is flux balance analysis?
Orth, J. D., Thiele, I., & Palsson, B. Ø. (2010) · Nature Biotechnology · doi:10.1038/nbt.1614 · Cited by 3,903
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vichai, V., & Kirtikara, K. (2006) · Nature Protocols · doi:10.1038/nprot.2006.179 · Cited by 3,671
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 2×
“The upregulation of glucose transporters (GLUTs) (4) and glycolytic enzymes, such as lactate dehydrogenase (LDH) and hexokinase 2, has been well documented in multiple types of cancer cells (2, 5).”
BackgroundGao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463
ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis
Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., Honma, Y., & Hayashi, J.-I. (2008) · Science · doi:10.1126/science.1156906 · Cited by 1,444 · cited 1×
“In addition, the hybrid metabolic phenotype maintains the cellular ROS at a moderate level so that cancer cells can benefit from ROS signaling (41) and still avoid DNA damage due to excessive ROS (42).”
BackgroundLeBleu, V. S., O’Connell, J. T., Gonzalez Herrera, K. N., Wikman, H., Pantel, K., Haigis, M. C., de Carvalho, F. M., Damascena, A., Domingos Chinen, L. T., Rocha, R. M., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3039 · Cited by 1,404
Tumor glycolysis as a target for cancer therapy: progress and prospects
Ganapathy-Kanniappan, S., & Geschwind, J.-F. H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-152 · Cited by 1,395
Oxidative stress inhibits distant metastasis by human melanoma cells
Piskounova, E., Agathocleous, M., Murphy, M. M., Hu, Z., Huddlestun, S. E., Zhao, Z., Leitch, A. M., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2015) · Nature · doi:10.1038/nature15726 · Cited by 1,269
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15081 · Cited by 992 · cited 1×
“We looked into the single-cell RNA-seq data of 317 BC cells (40), which are classified into a W/O cluster and a low-low cluster (Fig.”
MethodStructure of mammalian AMPK and its regulation by ADP
Xiao, B., Sanders, M. J., Underwood, E., Heath, R., Mayer, F. V., Carmena, D., Jing, C., Walker, P. A., Eccleston, J. F., Haire, L. F., et al. (2011) · Nature · doi:10.1038/nature09932 · Cited by 926
MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells
Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda, D., Sellers, K., Campos-Olivas, R., Graña, O., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.015 · Cited by 722
Bacterial Persister Cell Formation and Dormancy
Wood, T. K., Knabel, S. J., & Kwan, B. W. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.02636-13 · Cited by 703
Metabolic Plasticity in Stem Cell Homeostasis and Differentiation
Folmes, C. D. L., Dzeja, P. P., Nelson, T. J., & Terzic, A. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.10.002 · Cited by 669
How the Warburg effect supports aggressiveness and drug resistance of cancer cells?
Icard, P., Shulman, S., Farhat, D., Steyaert, J.-M., Alifano, M., & Lincet, H. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.001 · Cited by 643
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition
Sciacovelli, M., Gonçalves, E., Johnson, T. I., Zecchini, V. R., da Costa, A. S. H., Gaude, E., Drubbel, A. V., Theobald, S. J., Abbo, S. R., Tran, M. G. B., et al. (2016) · Nature · doi:10.1038/nature19353 · Cited by 584
A Mitochondrial Switch Promotes Tumor Metastasis
Porporato, P. E., Payen, V. L., Pérez-Escuredo, J., De Saedeleer, C. J., Danhier, P., Copetti, T., Dhup, S., Tardy, M., Vazeille, T., Bouzin, C., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.043 · Cited by 571
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer
Dupuy, F., Tabariès, S., Andrzejewski, S., Dong, Z., Blagih, J., Annis, M. G., Omeroglu, A., Gao, D., Leung, S., Amir, E., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.007 · Cited by 558 · cited 2×
“Compared with its isogenic nonmetastatic 67NR cells, 4T1 cells exhibit both enhanced OXPHOS and increased glycolytic activities (20).”
BackgroundInhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
Camarda, R., Zhou, A. Y., Kohnz, R. A., Balakrishnan, S., Mahieu, C., Anderton, B., Eyob, H., Kajimura, S., Tward, A., Krings, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4055 · Cited by 528
Imagable 4T1 model for the study of late stage breast cancer
Tao, K., Fang, M., Alroy, J., & Sahagian, G. G. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-228 · Cited by 525
Menk, A. V., Scharping, N. E., Moreci, R. S., Zeng, X., Guy, C., Salvatore, S., Bae, H., Xie, J., Young, H. A., Wendell, S. G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.040 · Cited by 484
Lamb, R., Ozsvari, B., Lisanti, C. L., Tanowitz, H. B., Howell, A., Martinez-Outschoorn, U. E., Sotgia, F., & Lisanti, M. P. (2015) · Oncotarget · doi:10.18632/oncotarget.3174 · Cited by 478
Predicting selective drug targets in cancer through metabolic networks
Folger, O., Jerby, L., Frezza, C., Gottlieb, E., Ruppin, E., & Shlomi, T. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.35 · Cited by 476
Metabolic Regulation in Pluripotent Stem Cells during Reprogramming and Self-Renewal
Zhang, J., Nuebel, E., Daley, G. Q., Koehler, C. M., & Teitell, M. A. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.10.005 · Cited by 471
Expression of glucose transporters in cancers
Szablewski, L. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.12.004 · Cited by 452
Flux balance analysis of biological systems: applications and challenges
Raman, K., & Chandra, N. (2009) · Briefings in Bioinformatics · doi:10.1093/bib/bbp011 · Cited by 437
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis
Terunuma, A., Putluri, N., Mishra, P., Mathé, E. A., Dorsey, T. H., Yi, M., Wallace, T. A., Issaq, H. J., Zhou, M., Killian, J. K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71180 · Cited by 428 · cited 1×
“Here we apply the AMPK and HIF-1 signatures to quantify the AMPK and HIF-1 activity of 45 human BC samples and 45 corresponding adjacent benign breast tissue samples (34) (see Materials and Methods for more details).”
MethodQiu, B., Ackerman, D., Sanchez, D. J., Li, B., Ochocki, J. D., Grazioli, A., Bobrovnikova-Marjon, E., Diehl, J. A., Keith, B., & Simon, M. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1507 · Cited by 394 · cited 1×
“Other HIF isoforms, such as HIF-2, which plays an important role in regulating lipid metabolism in clear cell renal cell carcinoma (52), could be integrated into the modeling framework in future to analyze the effect of various HIF isoforms in regulating cancer metabolism.”
BackgroundRegulation of T Lymphocyte Metabolism
Frauwirth, K. A., & Thompson, C. B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4661 · Cited by 371
Pacella, I., Procaccini, C., Focaccetti, C., Miacci, S., Timperi, E., Faicchia, D., Severa, M., Rizzo, F., Coccia, E. M., Bonacina, F., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720113115 · Cited by 344
Park, J. H., Vithayathil, S., Kumar, S., Sung, P.-L., Dobrolecki, L. E., Putluri, V., Bhat, V. B., Bhowmik, S. K., Gupta, V., Arora, K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.004 · Cited by 313
Self-citationThe Warburg effect and drug resistance
Bhattacharya, B., Mohd Omar, M. F., & Soong, R. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13422 · Cited by 298
Lactate Activates HIF-1 in Oxidative but Not in Warburg-Phenotype Human Tumor Cells
De Saedeleer, C. J., Copetti, T., Porporato, P. E., Verrax, J., Feron, O., & Sonveaux, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046571 · Cited by 277
Yu, L., Lu, M., Jia, D., Ma, J., Ben-Jacob, E., Levine, H., Kaipparettu, B. A., & Onuchic, J. N. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2074 · Cited by 272
Self-citationJia, D., Park, J., Jung, K., Levine, H., & Kaipparettu, B. (2018) · Cells · doi:10.3390/cells7030021 · Cited by 270
Self-citationDe Luca, A., Fiorillo, M., Peiris-Pagès, M., Ozsvari, B., Smith, D. L., Sanchez-Alvarez, R., Martinez-Outschoorn, U. E., Cappello, A. R., Pezzi, V., Lisanti, M. P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4401 · Cited by 259
Cheong, J.-H., Park, E. S., Liang, J., Dennison, J. B., Tsavachidou, D., Nguyen-Charles, C., Wa Cheng, K., Hall, H., Zhang, D., Lu, Y., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0497 · Cited by 245
Payen, V. L., Porporato, P. E., Baselet, B., & Sonveaux, P. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2098-5 · Cited by 220
From correlation to causation: analysis of metabolomics data using systems biology approaches
Rosato, A., Tenori, L., Cascante, M., De Atauri Carulla, P. R., Martins dos Santos, V. A. P., & Saccenti, E. (2018) · Metabolomics · doi:10.1007/s11306-018-1335-y · Cited by 213
Reactive Oxygen Species Regulate Hypoxia-Inducible Factor 1α Differentially in Cancer and Ischemia
Qutub, A. A., & Popel, A. S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00060-08 · Cited by 191
Interrogating the topological robustness of gene regulatory circuits by randomization
Huang, B., Lu, M., Jia, D., Ben-Jacob, E., Levine, H., & Onuchic, J. N. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005456 · Cited by 186
Self-citationGlutamate enrichment as new diagnostic opportunity in breast cancer
Budczies, J., Pfitzner, B. M., Győrffy, B., Winzer, K., Radke, C., Dietel, M., Fiehn, O., & Denkert, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.29152 · Cited by 142
A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration
Yizhak, K., Le Dévédec, S. E., Rogkoti, V. M., Baenke, F., de Boer, V. C., Frezza, C., Schulze, A., van de Water, B., & Ruppin, E. (2014) · Molecular Systems Biology · doi:10.15252/msb.20134993 · Cited by 139
Genome scale metabolic modeling of cancer
Nilsson, A., & Nielsen, J. (2016) · Metabolic Engineering · doi:10.1016/j.ymben.2016.10.022 · Cited by 128
Singleton, K. R., Crawford, L. A., Tsui, E. L., Manchester, H. E., Maertens, O., Liu, X., Liberti, M. V., Magpusao, A. N., Stein, E. M., Tingley, J. P., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.022 · Cited by 109
Systems biology analysis of drivers underlying hallmarks of cancer cell metabolism
Zielinski, D. C., Jamshidi, N., Corbett, A. J., Bordbar, A., Thomas, A., & Palsson, B. O. (2017) · Scientific Reports · doi:10.1038/srep41241 · Cited by 104
Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling
Tang, X., Ding, C.-K., Wu, J., Sjol, J., Wardell, S. E., Spasojević, I., George, D. J., McDonnell, D. P., Hsu, D. S., Chang, J. T., et al. (2016) · Oncogene · doi:10.1038/onc.2016.394 · Cited by 87
Bhattacharya, B., Low, S. H. H., Soh, C. K., Mustapa, N. K., Beloueche‐Babari, M., Koh, K. X., Loh, J. Y., & Soong, R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12668 · Cited by 84
RACIPE: a computational tool for modeling gene regulatory circuits using randomization
Huang, B., Jia, D., Feng, J., Levine, H., Onuchic, J. N., & Lu, M. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0594-6 · Cited by 62
Self-citationMathematical modeling of cancer metabolism
Medina, M. Á. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.02.004 · Cited by 36
Donti, T. R., Stromberger, C., Ge, M., Eldin, K. W., Craigen, W. J., & Graham, B. H. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.013466 · Cited by 25 · cited 2×
“completed, viable cells in each well were counted using a cell counter and the cell counts used to normalize the values (54).”
Method
Cited by
Loh, C.-Y., Chai, J., Tang, T., Wong, W., Sethi, G., Shanmugam, M., Chong, P., & Looi, C. (2019) · Cells · doi:10.3390/cells8101118 · Cited by 1,315
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Bi, K., He, M. X., Bakouny, Z., Kanodia, A., Napolitano, S., Wu, J., Grimaldi, G., Braun, D. A., Cuoco, M. S., Mayorga, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.015 · Cited by 618
Self-citationAbdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics
Panigrahi, D. P., Praharaj, P. P., Bhol, C. S., Mahapatra, K. K., Patra, S., Behera, B. P., Mishra, S. R., & Bhutia, S. K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.015 · Cited by 362
EMT Factors and Metabolic Pathways in Cancer
Georgakopoulos-Soares, I., Chartoumpekis, D. V., Kyriazopoulou, V., & Zaravinos, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00499 · Cited by 349
Metadata
- Authors
- Jia, D., Lu, M., Jung, K. H., Park, J. H., Yu, L., Onuchic, J. N., Kaipparettu, B. A., & Levine, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2019-02-07
- Volume
- 116
- Issue
- 9
- Pages
- 3909-3918
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2911915561
- Cited by
- 336
- References
- 56
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.